Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD Study

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms REBUILD
  • Sponsors Eli Lilly
  • Most Recent Events

    • 19 Nov 2018 Planned End Date changed from 10 Apr 2023 to 25 Jun 2022.
    • 19 Nov 2018 Planned primary completion date changed from 21 Mar 2022 to 31 May 2021.
    • 02 Nov 2018 Planned number of patients changed from 224 to 645.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top